Advertisement
Advertisement
AGEN
Agenus Inc.
6.67
USDSponsored
+0.14
+2.14%
Nov 03, 15:59 UTC -5
Closed
After-Market
6.67
0.00
+0.07%
Agenus Inc. (AGEN) Earnings
AGEN Earnings Reports
Positive Surprise Ratio
AGEN beat 21 of 43 last estimates.
49%
Next Report
Next Week
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$28.78M
/-$0.27
Implied change from Q2 26 (Revenue/ EPS)
-16.58%
/+2600.00%
Implied change from Q3 25 (Revenue/ EPS)
-4.81%
/-113.92%
Agenus Inc. earnings per share and revenue
On Aug 06, 2026, AGEN reported earnings of -0.01 USD per share (EPS) for Q2 26, missing the estimate of 0.05 USD, resulting in a -119.61% surprise. Revenue reached 34.50 million, compared to an expected 34.68 million, with a -0.52% difference. The market reacted with a -3.73% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 28.78 million USD, implying an increase of 2600.00% EPS, and decrease of -16.58% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ultragenyx Pharmaceutical Inc.
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$1.13
Actual
-$1.15
Surprise
-1.83%
Arvinas, Inc
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.71%
Oculis Holding AG Ordinary shares
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.42
Actual
-$0.30
Surprise
+28.03%
Precision BioSciences, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.65
Surprise
+25.03%
Amgen Inc
Report Date
Nov 03, 2026 For Q3 26
Estimate
$5.90
Actual
$6.45
Surprise
+9.16%
BioNTech SE - ADR
Report Date
Nov 03, 2026 For Q3 26
Estimate
$0.80
Actual
$1.81
Surprise
+126.53%
Rhythm Pharmaceuticals, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+15.83%
Mirum Pharmaceuticals, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.49
Actual
-$0.87
Surprise
-75.30%
Tarsus Pharmaceuticals, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$2.78
Actual
-$0.78
Surprise
+72.00%
Denali Therapeutics Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.54
Actual
-$0.64
Surprise
-17.95%
FAQ
What were Agenus Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Agenus Inc. reported EPS of -$0.01, missing estimates by -119.61%, and revenue of $34.50M, -0.52% below expectations.
How did the market react to Agenus Inc.'s Q2 2026 earnings?
The stock price moved down -3.73%, changed from $7.78 before the earnings release to $7.49 the day after.
When is Agenus Inc. expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Agenus Inc.'s next earnings report?
Based on 3
analysts, Agenus Inc. is expected to report EPS of -$0.27 and revenue of $28.78M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.